alexa Bacterial Infections And Cancer Therapy
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

5th International Congress on Bacteriology and Infectious Diseases
May 25-26, 2017 Chicago, USA

Ananda M Chakrabarty
University of Illinois College of Medicine, USA
Keynote: J Bacteriol Parasitol
DOI: 10.4172/2155-9597-C1-027
Abstract
It is widely recognized that anticancer drugs are pricey and often involve intravenous injections, thus limiting their usefulness and affordability to people in rich countries. People in poor countries or people living in rural areas often do not have access to potent anticancer drugs. Our efforts have been directed to protein products of pathogenic bacteria such as Pseudomonas aeruginosa for potential cancer treatment. One such cancer fighting protein, azurin, has shown significant tumor regression in mice. Since proteins are designated as biologics, and thus requiring to undergo stringent regulation by the USFDA for clinical trials, a company, CDG Therapeutics, Inc. (www.cdgti.com) has used a fragment of azurin termed p28, a peptide of 28 amino acids, for both pre-clinical and phase I clinical trials. P28 showed no toxicity in a variety of animals, whereupon the FDA approved a phase I trial of p28 in 15 stage IV cancer patients with solid tumors such as melanoma, colon, sarcoma, prostate and pancreas. These tumors were resistant to all conventional drugs and the patients were terminally ill with a life expectancy of about 6 months. When administered through intravenous injections, p28 demonstrated very little toxicity but significant beneficial effects including partial and complete regression of these drug resistant tumors in 4 patients. Encouraged by such results, the National Cancer Institute (NCI) sponsored a second phase I trial in 9 major hospitals in the US in pediatric brain tumor patients in October, 2013. That trial has been on-going for more than 2 years (http://clinicaltrials.gov/ct2/show/NCT01975116) suggesting that p28 not only demonstrated acceptable toxicity but significant regression of the tumors in some patients. Indeed, it is important to note that the USFDA has approved on December 02, 2015, the designation of azurin-p28 as an orphan drug for the treatment of brain tumor glioma. Another company Amrita Therapeutics in India (www.amritatherapeutics.com) has developed similar bacterial peptides as potential anticancer drugs, indicating the role that bacterial proteins/peptides can play in cancer therapy. Additionally, azurin gene has been cloned and expressed in plant cells. Oral consumption of such azurinexpressing plant extracts by mice allows tumor regression in tumor-bearing mice, demonstrating the potential usefulness of plant-expressed bacterial anticancer proteins in future cancer therapy.
Biography

Ananda M Chakrabarty is a Distinguished University Professor at the University of Illinois at Chicago College of Medicine. His research interest involves development of promiscuous bacterial protein/peptide drugs with anticancer, anti-viral and anti-parasitic activities. He is the Co-founder of two start-up companies, CDG Therapeutics Inc., in Chicago and Amrita Therapeutics in India..

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords